Reports

General Mills posted a 5% decrease in net sales for Q3 2025, totaling $4.84 billion. Operating income fell 2% to $891 million, and net income was $625.6 million. Diluted EPS was down 4% to $1.12, while adjusted EPS dropped 15% to $1.00. The company highlighted headwinds from retailer inventory reductions and slower performance in key snacking categories.

• Net sales decreased 5% to $4.84 billion, with a 5% decline in organic net sales.
• Operating income dropped 2% to $891 million, and net income fell 7% to $625.6 million.

Williams-Sonoma achieved net revenues of $2.46 billion in Q4 2024, a 8.1% year-over-year increase. Operating income reached $530.1 million with a record operating margin of 21.5%. Net earnings were $410.7 million, and diluted EPS came in at $3.28. The quarter was supported by robust comparable brand revenue growth and strong margin improvements.

• Q4 revenue grew 8.1% year-over-year to $2.46 billion.
• Operating income was $530.1 million with a record margin of 21.5%.

Ollie’s Bargain Outlet Holdings, Inc. saw a 2.8% increase in net sales and comparable store sales in Q4 2024. Despite this growth, operating income and net income were lower due to higher SG&A and pre-opening expenses. The company continued its expansion with 13 new stores and maintains a strong balance sheet.

• Q4 net sales increased to $667,084,000, up 2.8%.
• Comparable store sales grew by 2.8%.

Sportradar posted €307 million in revenue for Q4 2024, marking a 22% increase compared to the previous year. Despite strong operational growth and a 53% increase in adjusted EBITDA to €61 million, the company reported a net loss of €1.3 million due to significant foreign currency losses. The U.S. market demonstrated strong expansion, contributing 24% of total revenue for the quarter.

• Revenue rose 22% year-over-year to €307 million, driven by Betting & Gaming Content and Sports Content growth.
• Adjusted EBITDA increased 53% to €61 million, with margin expansion to 19.7%.

Five Below delivered a solid performance in Q4 2024, with net sales reaching $1.39 billion, representing a 4.0% increase year-over-year. The company reported a GAAP EPS of $3.39 and adjusted EPS of $3.48. Net income totaled $187.5 million, and operating income was $246.8 million. Despite a 3.0% decline in comparable sales, the company’s strategic execution and new store openings contributed positively.

• Net sales increased by 4.0% to $1.39 billion.
• GAAP EPS was $3.39, and adjusted EPS was $3.48.

GDS posted solid Q4 2024 results with increased revenue and a major net income boost, driven by asset monetization and growth in data center utilization.

• Revenue reached $368,620,000, up from $337,672,000 last year.
• Net income of $563,292,000, reversing last year's significant net loss.

Corporación América Airports (CAAP) delivered robust Q4 2024 results, with consolidated revenue of $461.1 million, a 26.3% increase year-over-year. Net income attributable to owners of the parent was $34.4 million, and adjusted EBITDA ex-IFRIC12 stood at $150.8 million. The company maintained a strong liquidity position with $439.8 million in cash and cash equivalents and demonstrated financial resilience across diverse geographies, partially offsetting softness in Argentina.

• Consolidated revenue increased 26.3% YoY to $461.1 million.
• Adjusted EBITDA ex-IFRIC12 was $150.8 million, down 49.5% YoY due to prior year one-time items.

Kingsoft Cloud saw significant revenue growth driven by AI cloud services, improved profitability metrics, and positive momentum in ecosystem partnerships during Q4 2024.

• Revenue grew to $305,802,000 in Q4 2024, driven by demand for AI and enterprise cloud projects.
• First-ever positive non-GAAP operating profit of $3,339,000 achieved.

Signet Jewelers reported $2.35 billion in revenue for Q4 2025, down 5.8% year-over-year. Operating income was $152.6 million, impacted by $200.7 million in impairment charges. Net income reached $100.6 million, with diluted EPS of $2.30. Adjusted diluted EPS was $6.62, slightly down from $6.73 in the prior year, despite cost pressures and lower sales volumes.

• Revenue declined by 5.8% to $2.35 billion compared to Q4 of FY24.
• Operating income decreased to $152.6 million, impacted by $200.7 million in impairment charges.

Vera Therapeutics reported a net loss of $152.1 million for the full year ended December 31, 2024, compared to a net loss of $96.0 million for the prior year. The company ended the year with $640.9 million in cash, cash equivalents, and marketable securities, which it believes is sufficient to fund operations through potential approval and U.S. commercial launch of atacicept.

• On track to announce primary endpoint results from the atacicept pivotal Phase 3 ORIGIN trial in IgA Nephropathy (IgAN) in 2Q 2025.
• BLA submission to the U.S. FDA for accelerated approval of atacicept planned in 2H 2025.

JOYY's Q4 2024 revenue declined to $549.4 million, with a net loss of $304.1 million, mainly due to a $454.9 million goodwill impairment. However, non-GAAP net income rose to $96.1 million and adjusted diluted EPS reached $1.77, reflecting strong underlying performance despite challenges.

• Revenue for Q4 2024 was $549.4 million, down from $569.8 million year-over-year.
• Net loss attributable to controlling interest was $304.1 million due to a $454.9 million non-cash goodwill impairment charge.

Liquidia Corporation continued to report losses in Q4 2024 as it prepares for potential YUTREPIA approval. Revenue remained modest, impacted by pump availability constraints. The company strengthened its cash position through amended financing agreements.

• Q4 revenue was $2,921,000, driven by the promotion agreement with Sandoz.
• Q4 net loss was $38,375,000 as R&D and legal expenses continued to grow.

Capricor Therapeutics posted a net loss for Q4 2024, with decreased revenue and increased operating expenses. The company maintained a strong cash position and continues advancing its pipeline and regulatory efforts.

• Q4 2024 revenue was $11.13 million, down from $12.09 million in Q4 2023.
• Net loss of $7.12 million, or $0.16 per share.

JJill, Inc. announced Q4 2024 results with net sales of $142.8 million, a decline of 4.9% year-over-year due to calendar shifts and loss from the 53rd week in the previous year. The company achieved a gross profit of $94.8 million and operating income of $5.1 million. Net income was $2.2 million, with diluted EPS of $0.14 and adjusted diluted EPS of $0.32. JJill continues to invest in store growth and system improvements while increasing its quarterly dividend by 14.3%.

• Net sales decreased 4.9% YoY to $142.8 million.
• Gross margin was 66.3%, down from 67.5% YoY.

In Q4 2024, Precigen reported $1.19 million in revenue and a net loss of $19.73 million, with an EPS of -$0.06. The company continued preparations for the anticipated commercial launch of PRGN-2012 in 2025 and successfully extended its cash runway into 2026.

• Q4 revenue reached $1.19 million.
• Q4 net loss was $19.73 million, with EPS of -$0.06.

Valneva posted €53 million in revenue for Q4 2024, but recorded a net loss of €36.9 million, impacted by higher R&D and finance expenses. Despite robust vaccine sales, profitability deteriorated from prior quarters.

• Q4 revenue reached approximately €53 million.
• Net loss of €36.9 million in the quarter, reversing prior profitability.

Sera Prognostics experienced a decline in revenue for Q4 2024 and continued investments in commercialization and research, resulting in a higher net loss. Despite this, the company raised additional funds to support its operations and future growth.

• Q4 2024 revenue was $24,000, down from $41,000 in Q4 2023.
• Net loss for the quarter was $8.58 million, compared to $7.93 million in the prior year.

The company delivered $91.3 million in revenue and $23.3 million in net income for Q4 2024, driven by high fleet utilization and increased charter activity.

• Generated $91.3 million in total revenue, including $5.9 million in insurance proceeds.
• Achieved fleet utilization of 98.3%.

In Q4 2024, Bakkt achieved total revenue of $1.80 billion, marking a 737.9% year-over-year increase, primarily fueled by record crypto trading volumes. The company reported a net loss of $40.4 million, a notable improvement from the previous year, and an adjusted EBITDA loss of $6.4 million. Operating losses also narrowed significantly as the company focused on its core crypto services and continued strategic realignment.

• Q4 revenue surged 737.9% year-over-year to $1.80 billion, driven by robust crypto trading activity.
• Net loss narrowed to $40.4 million, a 48.7% improvement from the previous year.

scPharmaceuticals reported strong growth in Q4 2024 with FUROSCIX revenue doubling year-over-year. Despite higher revenues, the company faced increased operating expenses leading to a net loss. Key milestones included FDA approval for an expanded FUROSCIX indication and continued expansion efforts in Integrated Delivery Networks.

• FUROSCIX revenue reached $12,150,000 in Q4 2024, up 99% year-over-year.
• Net loss widened to $18,845,000 compared to $13,812,000 in Q4 2023.

Aadi Bioscience, now Whitehawk Therapeutics, reported a net loss of $18.3 million for Q4 2024, compared to a net loss of $16.3 million in Q4 2023. Total revenue for the quarter was $7.2 million, primarily from FYARRO sales. The company also announced its rebranding and strategic focus on ADC assets, with cash and cash equivalents at $47.2 million as of December 31, 2024.

• Aadi Bioscience officially relaunched as Whitehawk Therapeutics, shifting its focus to advanced ADC therapies.
• The company reported a net loss of $18.3 million for Q4 2024, an increase from $16.3 million in the same period last year.